108 related articles for article (PubMed ID: 10917201)
1. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene.
Pang S
Cancer Gene Ther; 2000 Jul; 7(7):991-6. PubMed ID: 10917201
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
4. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A.
Zheng JY; Chen D; Chan J; Yu D; Ko E; Pang S
Cancer Gene Ther; 2003 Oct; 10(10):764-70. PubMed ID: 14502229
[TBL] [Abstract][Full Text] [Related]
5. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
7. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.
Peng W; Chen J; Huang YH; Sawicki JA
Gene Ther; 2005 Nov; 12(21):1573-80. PubMed ID: 16034457
[TBL] [Abstract][Full Text] [Related]
8. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.
Pang S; Dannull J; Kaboo R; Xie Y; Tso CL; Michel K; deKernion JB; Belldegrun AS
Cancer Res; 1997 Feb; 57(3):495-9. PubMed ID: 9012480
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer.
Lee CH; Liu M; Sie KL; Lee MS
Anticancer Res; 1996; 16(4A):1805-11. PubMed ID: 8712704
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
11. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Trofimova I; Dimtchev A; Jung M; Rosenthal D; Smulson M; Dritschilo A; Soldatenkov V
Cancer Res; 2002 Dec; 62(23):6879-83. PubMed ID: 12460902
[TBL] [Abstract][Full Text] [Related]
13. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
14. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
[TBL] [Abstract][Full Text] [Related]
15. [Constructing recombinant plasmid with prostate-specific membrane antigen promoter and reverse enhancer and comparing the transcription activity of enhancers in different directions].
Zeng H; Liao YC; Wang F; Wu Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Nov; 36(6):782-5. PubMed ID: 16334552
[TBL] [Abstract][Full Text] [Related]
16. [Clinical application for gene therapy in prostate cancer].
Gotoh A; Kamidono S; Chung LW
Hinyokika Kiyo; 1997 Nov; 43(11):829-33. PubMed ID: 9436031
[TBL] [Abstract][Full Text] [Related]
17. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
[TBL] [Abstract][Full Text] [Related]
18. Gene silencing in androgen-responsive prostate cancer cells from the tissue-specific prostate-specific antigen promoter.
Song J; Pang S; Lu Y; Yokoyama KK; Zheng JY; Chiu R
Cancer Res; 2004 Nov; 64(21):7661-3. PubMed ID: 15520164
[TBL] [Abstract][Full Text] [Related]
19. A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters.
van der Poel HG; McCadden J; Verhaegh GW; Kruszewski M; Ferrer F; Schalken JA; Carducci M; Rodriguez R
Cancer Gene Ther; 2001 Dec; 8(12):927-35. PubMed ID: 11781655
[TBL] [Abstract][Full Text] [Related]
20. Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.
Zhang L; Brereton HM; Hahn M; Froscio M; Tilley WD; Brown MP; Barritt GJ
Cancer Gene Ther; 2003 Aug; 10(8):611-25. PubMed ID: 12872143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]